Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 11059993.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Selective action at limbic cortical dopamine D(2)-like receptors could mediate atypical antipsychotic efficacy with few extrapyramidal side-effects. To test the hypothesis that quetiapine has 'limbic selective' D(2)/D(3) receptor occupancy in vivo. The high-affinity D(2)/D(3) ligand [(123)I]-epidepride and single photon emission tomography were used to estimate D(2)/D(3) specific binding and an index of relative percentage D(2)/D(3) occupancy in striatal and temporal cortical regions for quetiapine-treated patients (n=6). Quetiapine-, and previously studied typical-antipsychotic- and clozapine-treated patients were compared. Mean (s.d.) relative percentage D(2)/D(3) receptor occupancy by quetiapine was 32.0% (14.6) in striatum and 60.1% (17.2) in temporal cortex (mean daily dose 450 mg: range 300-700 mg/day). Quetiapine treatment resulted in limbic selective D(2)/D(3) blockade similar to clozapine and significantly higher than typical antipsychotics. Preliminary data suggest that limbic selective D(2)/D(3) receptor blockade is important for atypical drug action.
Medical subject headings
- Antipsychotic Agents
- Benzamides
- Corpus Striatum
- Dibenzothiazepines
- Iodine Radioisotopes
- Pyrrolidines
- Receptors, Dopamine D2